Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5608332 | 0.86 | POLB (0.50) | MEN1KMT2AHPGDESR1ESR2 | |
| SCHEMBL5608779 | 0.80 | POLB (0.48) | KMT2ANPC1RAB9APOLBALDH1A1 | |
| SCHEMBL11590449 | 0.78 | ESR1 (0.57) | MEN1KMT2APPARGHPGDESR1 | |
| SCHEMBL5608890 | 0.78 | KMT2A (0.42) | MEN1KMT2AHPGDNPC1RAB9A | |
| SCHEMBL5608927 | 0.76 | LMNA (0.47) | MEN1KMT2APPARGNPC1RAB9A | |
| SCHEMBL5608300 | 0.75 | HTT (0.42) | KMT2AHPGDNPC1RAB9APOLB | |
| SCHEMBL5608981 | 0.74 | POLB (0.46) | MEN1KMT2AHPGDNPC1RAB9A | |
| Acetaldehyde SCHEMBL27683945 | 0.73 | ESR1 (0.52) | MEN1KMT2APPARGHPGDESR1 | |
| SCHEMBL8319368 | 0.73 | PPARG (0.55) | MEN1KMT2APPARGHPGDESR1 | |
| SCHEMBL4544898 | 0.73 | L3MBTL1 (0.60) | MEN1KMT2APPARGHPGDESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169944-B2 | Optically active epoxy compounds and processes for their production | TOSOH CORPORATION (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20040063979-A1 | Optically active epoxy compounds and processes for their production | TOSOH CORPORATION (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1403260-A2 | Optically active epoxy compounds and processes for their production | Tosoh Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063979-A1 | Optically active epoxy compounds and processes for their production | CYP51A1, CYP11B1, PTGES | MEN1 2396/4885KMT2A 3888/4885PPARG 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.